New U.S. study finds mRNA-1273.815, a monovalent vaccine targeting the Omicron XBB.1.5 variant, generates higher neutralizing antibody titers compared to its bivalent counterpart. The study supports updating to an XBB.1.5-based monovalent vaccine for the 2023-24 campaign to combat emerging variants.
Mayo Clinic and Ayble Health Launch Integrated Care Model for GI Patients
What You Should Know: – Ayble Health, a digital health platform dedicated to empowering patients with chronic GI conditions, has joined forces with the Mayo
November 21, 2023